权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Drug-Drug Interactions Involving Antidiabetic Agents

涉及抗糖尿病药物的药物相互作用

基本信息

批准号：
9282425
负责人：
Sean Hennessy
金额：
$ 58.18万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-15 至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9282425
关键词：
Accident and Emergency department Adherence Admission activity Adverse drug event Adverse effects Affect Antidiabetic Drugs Biological CYP2C9 gene Case Fatality Rates Case Series Case Study Chronic Clinical Clinical Decision Support Systems Coma Cytochrome P450 Data Dementia Diabetes Mellitus Drug Interactions Elderly Enzymes Fright Glimepiride Glipizide Glyburide Goals Health Healthcare Hospitalization Hospitals Hypoglycemia In Vitro Incidence Individual Injury Insulin Knowledge Life Metabolic Pathway Metformin Modeling Myocardial Non-Insulin-Dependent Diabetes Mellitus Oral Pathway interactions Patients Persons Pharmaceutical Preparations Pharmacoepidemiology Pharmacology Pharmacotherapy Population Prevalence Probability Public Health Publishing Quality of life Recommendation Research Risk Self-control as a personality trait Subgroup Sulfonylurea Compounds System Time Translational Research Trimethoprim-Sulfamethoxazole base clinically actionable clinically significant cohort design glycemic control high risk high throughput screening insulin secretagogues insulin secretion mortality nateglinide public health relevance repaglinide satisfaction simulation symposium

项目摘要

DESCRIPTION (provided by applicant): Known drug-drug interactions (DDIs) are responsible for 13 percent of adverse drug events and 4.8 percent of hospital admissions in older adults. Even these high figures may understate the true impact of DDIs because they include only the effects of known interactions. Many clinically important DDIs take years to discover. Given the widespread and growing use of multiple medications by persons with diabetes, there is tremendous potential for DDIs to occur in this population. Of the ten most commonly used second-line antidiabetic agents, five are insulin secretagogues, which, based on known metabolic pathways, may interact with many commonly- prescribed medications. DDIs involving insulin secretagogues can cause serious hypoglycemia, which can be immediately life-threatening and have cause long-term consequences. The broad objective of this project is to produce clinically-actionable knowledge about which drugs interact with insulin secretagogues to cause serious hypoglycemia, as well as the time-course of such interactions and the subgroups most susceptible to these DDIs. We will achieve this objective by taking a translational science approach to DDIs in which we 1) perform high-throughput simulation of potential DDIs based on pharmacologic knowledge; 2) perform high-throughput screening of healthcare data; and then 3) confirm (or refute) and elucidate selected high-probability DDIs in an independent population by conducting in-depth pharmacoepidemiologic studies. This project will produce clinically-actionable knowledge about which drugs interact with secretagogues to cause severe hypoglycemia, and generalizable biological knowledge about the drugs and pathways involved in these interactions.

描述（由申请人提供）：已知的药物-药物相互作用（DDI）是老年人13%的药物不良事件和4.8%的住院率的原因。即使是这些高数字也可能低估了DDI的真实影响，因为它们只包括已知相互作用的影响。许多临床上重要的DDI需要数年才能发现。鉴于糖尿病患者广泛使用多种药物，这一人群发生DDI的可能性很大。在十种最常用的二线抗糖尿病药物中，五种是胰岛素促分泌剂，基于已知的代谢途径，其可能与许多常用处方药相互作用。涉及胰岛素促分泌素的DDI可引起严重的低血糖，这可立即危及生命并造成长期后果。该项目的广泛目标是产生关于哪些药物与胰岛素促分泌素相互作用导致严重低血糖的临床可操作知识，以及这种相互作用的时间过程和最易受这些DDI影响的亚组。我们将通过对DDI采取转化科学方法来实现这一目标，其中我们1）基于药理学知识对潜在DDI进行高通量模拟; 2）对医疗保健数据进行高通量筛选;然后3）通过进行深入的药物流行病学研究，在独立人群中确认（或反驳）并阐明选定的高概率DDI。该项目将产生关于哪些药物与促分泌素相互作用导致严重低血糖的临床可操作的知识，以及关于这些相互作用中涉及的药物和途径的可推广的生物学知识。